SBIR/STTR Research Award
IGF::OT::IGF : Novel Treatment for Drug-induced Respiratory Depression. September 18, 2014 - March 17, 2014. N01DA-14-2239.
Award amount
$148,583Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Cortex Pharmaceuticals Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- NIDA
Research abstract
Using plethysmographic measurements in various groups of rats, the proposed studies will determine the potency, latency to onset and duration of action of CX1942 when adminisstered either prior to, simultaneously with or subsequent to administration of either an opiate (morphine or fentanyl), a benzodiazepine (diazeman or alprazolam) in combination with an opiate or a benzodiazepine in combination with ethanol. PUBLIC HEALTH RELEVANCE
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)